GLOW

GLOW is a compounded peptide blend formulated for research into skin rejuvenation, collagen synthesis, and connective tissue repair. At 70 mg total, it delivers a therapeutically significant dose of GHK-Cu — the copper-binding tripeptide responsible for stimulating fibroblast collagen production, resetting aging gene expression, and promoting wound healing — alongside supporting doses of TB-500 and BPC-157.

GHK-Cu constitutes 71% of the blend. Decades of research have established it as one of the most effective naturally occurring peptides for collagen type I, III, and IV synthesis, antioxidant activity, and gene regulation. The remaining 29% is split between TB-500 (for angiogenesis and actin polymerization) and BPC-157 (for anti-inflammatory signalling and growth factor upregulation).

As a blended product, GLOW does not have a single CAS number. Each component retains its individual pharmacology, and the blend is designed to produce synergistic regenerative effects that exceed what any single peptide achieves in isolation.

// GHK-Cu — COLLAGEN & GENE REGULATION

GHK-Cu binds copper(II) ions via its histidine and lysine residues, forming a complex that activates TGF-β signalling and upregulates fibroblast collagen synthesis. It modulates over 4,000 human genes — resetting aging expression patterns toward younger phenotypes. It also upregulates antioxidant enzymes and promotes wound contraction.

// TB-500 — ANGIOGENESIS & TISSUE MIGRATION

The active fragment of thymosin β4 promotes actin polymerization, enabling cell migration into damaged tissue. It upregulates VEGF and promotes new capillary formation, increasing vascular supply to remodelling skin and connective tissue.

// BPC-157 — ANTI-INFLAMMATORY SUPPORT

BPC-157 modulates nitric oxide synthesis, downregulates NF-κB signalling, and reduces pro-inflammatory cytokines (TNF-α, IL-6, IL-1β). By resolving chronic inflammation that degrades collagen and impairs fibroblast activity, BPC-157 creates the permissive microenvironment for GHK-Cu and TB-500 to operate effectively.

The GLOW blend is based on compounded preclinical and clinical research for each individual component. GHK-Cu has the largest evidence base — including multiple human studies on wound healing, hair loss, and skin aging — while TB-500 and BPC-157 data is primarily preclinical with growing anecdotal clinical use.

Synergy between the components is biologically plausible and supported by mechanistic overlap, but controlled trials of the specific GLOW formulation have not been published.